David Rodríguez de Vera Gómez

Mr. David Rodríguez de Vera Gómez


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MOMercedes Ortiz-Romero
Mercedes Ortiz-Romero
Gabriel Gijon-NogueronGabriel Gijon-Nogueron
Gabriel Gijon-Nogueron
PGpablo rodriguez de vera gomez
pablo rodriguez de vera gomez
DGDavid Rodríguez de Vera Gómez
David Rodríguez de Vera Gómez
NENerea Escribano
Nerea Escribano
LFLuis María Gordillo Fernández
Luis María Gordillo Fernández
Background/Objectives: Plantar fasciitis (PF) is a leading cause of heel pain and functional impairment in adults. Laser therapy, in its low-intensity laser therapy (LLLT), high-intensity laser therapy (HILT), and photobiomodulation (PBMT) modalities, has been proposed as a non-invasive alternative, although its clinical effectiveness remains a subject of debate. The aim of this systematic review and meta-analysis was to evaluate the efficacy of laser therapy in reducing pain, improving function, and modifying fascial thickness in patients with PF. Methods: A comprehensive search was conducted in PubMed, Embase, and PEDro (last search: August 2025). Randomized controlled trials comparing laser therapies versus placebo or alternative physical interventions were included. Two reviewers performed study selection, data extraction, and risk of bias assessment using the PEDro scale. Random-effects meta-analyses were performed for pain (VAS), heel tenderness (HTI), function (FFI, AOFAS, ASQoL, SF-36), and fascial thickness, expressing effects as standardized mean differences (SMDs) or mean differences (MDs). Results: Thirteen trials with 784 participants were included. Laser therapy showed a significant improvement in heel tenderness (SMD = −0.40; 95% CI −0.71 to −0.09; I2 = 0%). No significant differences were observed in overall pain (SMD = −0.18), function (SMD = 0.20), or fascial thickness (MD = −0.18 mm). Pain and function analyses showed high heterogeneity. Conclusions: Laser therapy may reduce heel tenderness in plantar fasciitis, but it does not consistently improve overall pain, function, or fascial thickness. Its use should be considered as a therapeutic adjunct and not as a primary intervention. Larger trials with standardized protocols are needed.

10 February 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
MOMercedes Ortiz-Romero
Mercedes Ortiz-Romero
DGDavid Rodríguez de Vera Gómez
David Rodríguez de Vera Gómez
PGpablo rodriguez de vera gomez
pablo rodriguez de vera gomez
LFLuis María Gordillo Fernández
Luis María Gordillo Fernández
Background/Objectives: Diabetic foot disease is one of the most severe and disabling complications of type 2 diabetes mellitus, resulting from the interaction between peripheral neuropathy, peripheral arterial disease, and infection. It is associated with a high risk of ulceration, lower-limb amputation, hospitalisation, and mortality, and is currently recognised as a marker of advanced systemic vascular disease. Although glucagon-like peptide-1 receptor agonists have demonstrated robust cardiometabolic benefits, their potential impact on diabetic foot disease outcomes remains insufficiently explored. Methods: This narrative review critically synthesises clinical, experimental, and translational evidence evaluating the association between glucagon-like peptide-1 receptor agonist therapy and diabetic foot disease-related outcomes. A comprehensive literature search was conducted in PubMed and related databases, focusing on studies published over the last decade that assessed diabetic peripheral neuropathy, foot ulceration, amputations, hospitalisations, and mechanistic pathways potentially linking glucagon-like peptide-1 receptor agonists to diabetic foot pathophysiology. Results: Available observational studies and population-based analyses suggest that glucagon-like peptide-1 receptor agonist treatment is associated with a reduced incidence of diabetic foot ulcers, lower-limb amputations, and related hospitalisations. Experimental and translational data provide biological plausibility for these findings, demonstrating neuroprotective effects, attenuation of neuroinflammation, and improvement of endothelial function and microvascular perfusion, as well as modulation of inflammatory and reparative pathways involved in wound healing. These pleiotropic actions extend beyond glycaemic control and may influence the natural history of diabetic foot disease. Conclusions: Glucagon-like peptide-1 receptor agonists emerge as promising therapeutic agents with potential benefits in the prevention and progression of diabetic foot disease. Their integrated neurovascular and immunometabolic effects may contribute to improved clinical outcomes and a reduced healthcare burden. Prospective studies and dedicated clinical trials are warranted to confirm these associations and to define the role of glucagon-like peptide-1 receptor agonists in the multidisciplinary management of diabetic foot disease.